Cargando…

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer

OBJECTIVE: Considering the striking evidence revealed by immunotherapy in advanced or metastatic bladder cancer, investigators have explored neoadjuvant immunotherapy and chemoimmunotherapy in muscle-invasive bladder cancer (MIBC). Currently, there have been a large number of studies reporting varie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hualin, Yang, Wenjie, Xue, Xiaoqiang, Li, Yingjie, Jin, Zhaoheng, Ji, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428578/ https://www.ncbi.nlm.nih.gov/pubmed/36059550 http://dx.doi.org/10.3389/fimmu.2022.986359

Ejemplares similares

Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients
por: Chen, Hualin, et al.
Publicado: (2022)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients
por: Chen, Hualin, et al.
Publicado: (2023)

Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients
por: Chen, Hualin, et al.
Publicado: (2023)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
por: Xing, Wenqun, et al.
Publicado: (2021)

A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
por: Liu, Wei, et al.
Publicado: (2022)

Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer
por: Zhang, Qi, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
por: Lu, Meng, et al.
Publicado: (2022)

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
por: Jiang, Juan, et al.
Publicado: (2022)

SHOX2 promotes prostate cancer proliferation and metastasis through disruption of the Hippo-YAP pathway
por: Yang, Wenjie, et al.
Publicado: (2023)

A comprehensive analysis of the FOX family for predicting kidney renal clear cell carcinoma prognosis and the oncogenic role of FOXG1
por: Yang, Wenjie, et al.
Publicado: (2022)

Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features
por: Yang, Nong, et al.
Publicado: (2023)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer
por: Wang, Weizhuo, et al.
Publicado: (2023)

Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy
por: Yang, Wenjie, et al.
Publicado: (2023)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
por: Fukuda, Keitaro
Publicado: (2023)

Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer: A protocol for systematic review and meta-analysis
por: Zhu, Qunying, et al.
Publicado: (2023)

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report
por: Cao, Chuanzhen, et al.
Publicado: (2021)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020)

PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling
por: Chen, Hualin, et al.
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Liu, Shuai, et al.
Publicado: (2022)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon
por: Mutlu, Arda Ulaş, et al.
Publicado: (2023)

Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer
por: Benítez, Raquel, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
por: Gao, Yang, et al.
Publicado: (2022)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
por: Xu, Jiawei, et al.
Publicado: (2022)

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
por: Zhou, Long, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lr9hbdcc6k3i0vqarbf1uckpls